Results 141 to 150 of about 44,547 (282)

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6509-6532, August 2026.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano, Line L. Haurum, Christine R. Schwarz, Francesca Porcellati, Andreas Andersen   +4 more
wiley   +1 more source

Impact of Sleeve Gastrectomy Versus Intensive Lifestyle Modifications With Obesity Management Medications on BMI Trajectory and Target Attainment: A Prospective Matched Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7126-7136, August 2026.
ABSTRACT Aims To compare sleeve gastrectomy (SG) with intensive lifestyle modification combined with obesity management medications (ILM/OMMs) in adults with severe obesity, focusing on BMI trajectory, time to achieving clinically meaningful weight loss, and metabolic outcomes in a real‐world clinical setting.
Maria Francesca Russo, Giovanni Casella, Giulia Angelini, Sara Russo, James Casella‐Mariolo, Vito D'Andrea, Giulio Illuminati, Lidia Castagneto‐Gissey   +7 more
wiley   +1 more source

Inhibition of Gastric Inhibitory Polypeptide Receptor Signaling in Adipose Tissue Reduces Insulin Resistance and Hepatic Steatosis in High-Fat Diet–Fed Mice

Diabetes, 2017
Erina Joo, N. Harada, S. Yamane, T. Fukushima, Daisuke Taura, Kanako Iwasaki, Akiko Sankoda, Kimitaka Shibue, Takanari Harada, Kazuyo Suzuki, A. Hamasaki, N. Inagaki   +11 more
semanticscholar   +1 more source

Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6533-6549, August 2026.
ABSTRACT GLP‐1RAs are increasingly used for their glucose‐lowering and weight‐management effects, but many patients discontinue them. In this narrative review we aim to review real‐world, quantitative and qualitative GLP‐1RA discontinuation, adherence, and persistence evidence as it aligns with an established conceptual framework for understanding ...
Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher   +4 more
wiley   +1 more source

Gut microbiota DPP4-like enzymes are increased in type-2 diabetes and contribute to incretin inactivation

Genome Biology
Background The gut microbiota controls broad aspects of human metabolism and feeding behavior, but the basis for this control remains largely unclear. Given the key role of human dipeptidyl peptidase 4 (DPP4) in host metabolism, we investigate whether ...
Marta Olivares, Paula Hernández-Calderón, Sonia Cárdenas-Brito, Rebeca Liébana-García, Yolanda Sanz, Alfonso Benítez-Páez   +5 more
doaj   +1 more source

Radioimmunoassay of Gastric Inhibitory Polypeptide in Plasma

Clinical Chemistry, 1992
J, Wishart, H A, Morris, M, Horowitz
openaire   +2 more sources

Acute GIP and GLP‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7280-7290, August 2026.
ABSTRACT Aims While being recognised for stimulating pancreatic insulin secretion, GIP and GLP‐1 exert various extrapancreatic effects relevant in the context of incretin‐based therapies. Here, we evaluated the extrapancreatic effects of GIP and GLP‐1, separately and combined, on postprandial physiology in totally pancreatectomised individuals ...
Liva S. L. Krogh, Maja B. Hansen, Natasha C. Bergmann, Carsten P. Hansen, Bolette Hartmann, Jens J. Holst, Filip K. Knop, Asger B. Lund, Lærke S. Gasbjerg   +8 more
wiley   +1 more source

Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes

, 2009
Recent research suggests that long-term ablation of gastric inhibitory polypeptide (GIP) receptor signalling can reverse or prevent many of the metabolic abnormalities associated with dietary and genetically induced obesity-diabetes.
McClean, Paula L., Hunter, Kerry, Irwin, Nigel, Flatt, Peter R., Patterson, Steven; id_orcid   +4 more
core   +1 more source

QBP1 Peptide as a Potential Anti‐Amyloidogenic Therapy for Type 2 Diabetes: An In Vitro Study

Advanced Science, Volume 13, Issue 37, 3 July 2026.
The anti‐amyloidogenic peptide QBP1 effectively halts human islet amyloid polypeptide (hIAPP) aggregation, preventing the formation of toxic β‐structured intermediates. Through a combination of biophysical assays, molecular dynamics, and cell‐based studies, QBP1 is shown to preserve β‐cell viability and metabolic homeostasis, positioning it as a ...
María M. Tejero‐Ojeda, Ada Bernaus Vives, Michał Wojciechowski, Dinh Quoc Huy Pham, Mateusz Chwastyk, Mario Vallejo, Anna Novials, Douglas V. Laurents, Mariano Carrión‐Vázquez   +8 more
wiley   +1 more source

DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes

Vascular Health and Risk Management, 2017
Plamen Kozlovski,1 Vaishali Bhosekar,2 James E Foley3 1Novartis Pharma AG, Basel, Switzerland; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Introduction: Dipeptidyl peptidase-4 (DPP ...
Kozlovski P, Bhosekar V, Foley JE
doaj